Medicilon Logo
search icon search icon language icon contact icon menu icon
Medicilon Logo
search icon close search icon language icon contact icon menu icon
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Join Medicilon at ELRIG Drug Discovery 2021

Page View:

ELRIG drug discovery.png

19-20 Oct. 2021, Medicilon welcomes you to join us at Europe’s largest meeting for life sciences industry professionals, ELRIG’s annual Drug Discovery meeting.

This year, Drug Discovery 2021 promises to be particularly special event, providing a platform for the whole drug discovery community to meet at a free to attend, in-person event, where members of ELRIG’s community may:

 Re-connect with colleagues, as well as hear stories from scientists who have been responsible for combatting COVID-19 in the session tracks on infection and diagnostics.

 Re-invent the process of drug discovery, by building diverse partnerships with even greater emphasis on efficiency, automation,  and remote operation in our two session tracks of screening and chemistry.

 Re-imagine and create a new vision for drug discovery, with insights from our innovation and disruptive strategies tracks.

Medicilon looks forward to meeting you at Booth #F15. With more than 17 years of experience in preclinical R&D, we’d like to build partnership with you and assist your drug R&D projects in:

Medicilon Preclinical CRO

About Medicilon

From its inception in 2004, Shanghai Medicilon Inc. (STAR Market stock code: 688202.SH) has been committed to providing comprehensive research and development (R&D) services to pharmaceutical companies, research institutions, and any organizations working in the preclinical space, with the primary objective of supporting and accelerating pharmaceutical, biopharmaceutical R&D worldwide.

Relevant newsRelevant news